Sign Up Now to Download a Free Research Report on HALO
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Halozyme Therapeutics, Inc.
Halozyme Therapeutics shares surged 18.40 percent on nearly five times the average daily volume Thursday to close at $7.98 a share. The company reported data from a clinical trial of its pancreatic cancer drug, PEGPH20, showed it may make tumors more vulnerable to therapy.
Going forward ... (see research report)
Subscribe to News Feeds